🕒 Last update: loading…

Stock NewAmsterdam Pharma Company N.V. NAMS

NewAmsterdam Pharma Company N.V. — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met.

  • ✅ Price trend passed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): the price has been multiplied by at least 1.5.

Price change 2021 → 2022: 11.79%

Price change 2022 → 2023: 2.48%

Price change 2023 → 2024: 130.08%

Price change 2024 → 2025: 36.50%

Price change 2025 → 2026: -31.13%

Price change 2026 (year to date): -31.36%

Financial growth

Revenue CAGR (6 years): N/A

Earnings CAGR (6 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.00

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -10.74

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 38.97% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
NewAmsterdam Pharma Company N.V.–0.00–🔒
Addus HomeCare Corporation18.60.19+11.7 %★ 4/5
Pediatrix Medical Group, Inc.14.00.76+2.1 %–
Vir Biotechnology, Inc.–0.24+115.2 %–
Fleury S.A.16.31.05+16.2 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by NewAmsterdam Pharma Company N.V. over the latest fiscal years.

Revenue
22.5 m USD
fiscal year 2025
Net income
-204 m USD
fiscal year 2025
Net margin
-905.7 %
fiscal year 2025
Market cap
2.4 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
2022103 m-22.6 m-22.0 %n/a
202314.1 m-177 m-1,255.8 %-86.3 %
202445.6 m-242 m-530.2 %+223.4 %
202522.5 m-204 m-905.7 %-50.6 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by NewAmsterdam Pharma Company N.V. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
23.62
safe zone (above 2.99)
Piotroski Score
1 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
2.07 x
moderate debt
Fiscal year20212022202320242025
Cash and investments60.4 m468 m340 m834 m636 m
Total Debt186,511126,00060,000448,000202,000
Net Debt-60.2 m-468 m-340 m-771 m-490 m
Equity56.6 m430 m288 m758 m683 m
Total assets68.0 m478 m347 m865 m769 m
Operating cash flow-29.5 m10.7 m-141 m-159 m-148 m
Investments (capex)24,000221,00024,000672,000246,000
Free cash-flow-29.5 m10.4 m-141 m-159 m-148 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-11.68 x
Price / book value3.93 x
Return on Equity (ROE)-31.4 %
Return on Invested Capital (ROIC)-37.0 %
Net margin-789.9 %
Debt / equity0.00 x
Current ratio11.76 x
Free cash-flow yield-6.3 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Valuation and competitors

NewAmsterdam Pharma Company N.V. compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
NewAmsterdam Pharma Company N.V.2.3 bnn/a-905.7 %
BioAge Labs, Inc. BIOA201 mn/a-896.1 %
Amylyx Pharmaceuticals, Inc. AMLX3.7 bnn/a0.0 %
Madrigal Pharmaceuticals, Inc. MDGL9.2 bnn/a-30.1 %
MetaVia Inc. MTVA9.4 mn/a0.0 %
Viking Therapeutics, Inc. VKTX3.4 bnn/a0.0 %
Acumen Pharmaceuticals, Inc. ABOS16.2 mn/a0.0 %
CervoMed Inc. CRVO21.5 mn/a0.0 %
Denali Therapeutics Inc. DNLI3.2 bnn/a0.0 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering NewAmsterdam Pharma Company N.V. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
11 analysts

Breakdown of ratings

strong buy 0buy 10hold 1sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 6 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in NewAmsterdam Pharma Company N.V.

Free float
68.2 %
share of freely traded shares
Large funds tracked
25
hold the stock as of 2026Q2
Executives (insiders)
1 / 6
1 purchases, 6 sales in 130 days

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
Capital World Investors12.2 m414 m0.1 %+10.1 %2026Q2
Fidelity10.3 m350 m0.0 %+18.0 %2026Q2
Viking Global Investors4.2 m142 m0.4 %0.0 %2026Q2
Maverick Capital3.3 m111 m1.0 %+49.5 %2026Q2
Duquesne Family Office3.1 m104 m2.4 %0.0 %2026Q2
Goldman Sachs1.5 m52.4 m0.0 %-20.6 %2026Q2
Citadel Advisors1.3 m43.8 m0.0 %+81.4 %2026Q2
T. Rowe Price1.2 m39.6 m0.0 %n/a2026Q2

Latest insider transactions

DatePersonSideAmount
30/09/2026Kastelein Johannes Jacob Pietersale1.3 m USD
14/09/2026Davidson Michael H.purchase226,500 USD
04/09/2026Smither John Wsale40,512 USD
24/08/2026Kastelein Johannes Jacob Pietersale3.4 m USD
20/07/2026Kooij Louise Frederikasale2.1 m USD
20/07/2026Kooij Louise Frederikasale990,029 USD

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 16/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

Listing exchange
Nasdaq
IPO: 09/02/2021
ISIN code
NL00150012L7
Workforce
68
full-time employees
Chief executive
Michael Harvey Davidson FACC, Facp.,
?

Frequently asked questions about NewAmsterdam Pharma Company N.V.

What is the NewAmsterdam Pharma Company N.V. share price?

Latest recorded price: 20.14 USD on 13/11/2026, for a market cap of 2.4 bn USD.

What is the revenue of NewAmsterdam Pharma Company N.V.?

22.5 m USD for fiscal year 2025, with net income of -204 m USD (net margin -905.7 %).

What do analysts say about NewAmsterdam Pharma Company N.V.?

Out of 11 analysts: 10 buy or strong buy, 1 hold, 0 sell or strong sell.

How many employees does NewAmsterdam Pharma Company N.V. have?

68 full-time employees according to the latest published profile.

Who runs NewAmsterdam Pharma Company N.V.?

Michael Harvey Davidson FACC, Facp., is the company's chief executive.

Which large funds own NewAmsterdam Pharma Company N.V.?

As of 2026Q2, among the large funds tracked: Capital World Investors, Fidelity, Viking Global Investors, Maverick Capital, Duquesne Family Office.

07

Similar stocks